Tag Archives: drug discovery

Hot Investor Mandate 3: Boston-Based VC Firm Makes Pre-Seed/Seed Investments in Data-Driven Technologies Including AI, Drug Discovery, and Computational Biotech

31 May

A venture firm headquartered in Boston, MA focus on pre-seed and seed stage investments, typically with an initially investment of $500K to $1M as part of the company’s first institutional funding. The firm prefers companies located in the USA and Canada. The firm will make 5-10 new investments over the next 12 months.

The firm partners with entrepreneurs solving real-world problems with data and machine learning, focusing on applications of frontier technologies such as AI, computational biotech, connected sensors, AR/VR, and blockchain. Past investments include biomedical and genomics data analytics platforms, data and analysis tools for drug discovery, and related areas.

The firm desires experienced management teams with a vision for the future. The firm can take a board seat when they have specific expertise in the area, and does not have an equity target. Strong technical teams who have a deep understanding of their markets is desired, though the firm is comfortable partnering with very early-stage (pre-product) companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: VC Firm with Offices in New England Seeks Digital Health Platform Companies Relating to Drug Discovery, Delivery, and Manufacturing

24 May

A venture capital firm with offices in the New England region currently manages four funds, two of which are dedicated to sector specific investments. The first focuses on healthcare and life science investments, while the other is focused on investing in built environment technology. On average, the initial size of investment is up to $1M, and the firm has the capacity to invest $2-4 M after the initial investment. The firm initially invests from Seed to Series A typically, but has come in at later stage investments. The firm is willing to lead in seed rounds and co-invest in later rounds. The firm has a preference for investing in US, but can invest globally. The firm is actively seeking new investment opportunities.

The firm is a flexible investor that is currently looking for life science platforms relating to drug discovery, delivery, and manufacturing and digital health companies. The firm typically does not invest in therapeutics, medical devices, and diagnostics. The firm prefers enterprise to direct-to-consumer health IT companies. In addition, the firm prefers companies that meet at least $1M revenue traction on the health IT side.

The firm will invest in privately held companies only. The firm has no specific requirements for the management team. The firm may take a board seat in applicable cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Big Data in Drug Discovery: 5 Experts Share Their Thoughts at RESI Boston

7 Sep

By Michael Quigley, VP of Investor Research, LSN

mike-2To reduce the massive costs associated with getting a new drug approved, many startups, large pharma companies, venture funds, and others are looking to big data for a solution. These firms are researching, partnering, and investing into machine learning and artificial intelligence systems that scour through massive drug and target libraries to more quickly identify potential candidates than a team of researchers could. These technologies are leveraging all kinds of scientific and medical data including chemical, biologic, genomic and clinical datasets to best identify candidates. Companies are touting their tech promises “years” of savings and lower failure rates in research that can now be done through advanced algorithms. This may seem like quite the promise, but if you look at the number and size of deals in the space just in the past year, it’s clear that big players are listening (1, 2, 3, 4, 5, 6).

At RESI Boston this September 26th we are bringing together a panel of 5 experts in this space to discuss their thoughts on the challenges and opportunities that the use of Big Data in Drug Discovery currently faces. These speakers include a promising company with an emerging drug discovery technology, a massive CRO, and three venture funds, all actively working in this space. Look below to see the speakers for yourself. This is another cutting-edge session you won’t want to miss!

  • Richard Soll, Senior Vice President, Research Service Division, WuXi AppTec (moderator)
  • Gini Deshpande, Founder and Chief Executive Officer, NuMedii, Inc.
  • Millie Liu, Founding Partner, Managing Director, Procyon Ventures
  • Dylan Morris, Partner, CRV
  • Annie Hazlehurst, Founder, Faridan
  1. http://www.fiercebiotech.com/medtech/gsk-taps-baltimore-s-insilico-for-ai-based-drug-discovery
  2. https://www.reuters.com/article/us-astrazeneca-ai-berg/astrazeneca-taps-ai-for-drug-discovery-in-deal-with-berg-idUSKCN1B81G1
  3. http://www.koreabiomed.com/news/articleView.html?idxno=1254
  4. http://www.prnewswire.com/news-releases/wuxi-nextcode-ai-points-to-new-therapeutic-approaches-to-cardiovascular-disease-and-cancer-in-yale-nature-study-300457412.html
  5. http://www.wired.co.uk/article/benevolent-ai-london-unicorn-pharma-startup
  6. http://www.prnewswire.com/news-releases/numedii-inc-announces-new-partnership-to-discover-and-advance-new-treatments-for-idiopathic-pulmonary-fibrosis-300437651.html

%d bloggers like this: